References
1. Dumitru A., Dobrica E.C., Croitoru A., Cretoiu S.M., Gaspar B.S. Focus on PD-1/PD-L1 as a Therapeutic Target in Ovarian Cancer. Int. J. Mol. Sci. 2022; 23 (20): 12067. DOI: https://doi.org/10.3390/ijms232012067
2. Hamanishi J., Mandai M., Ikeda T., Minami M., Kawaguchi A., Murayama T., Kanai M., Mori Y., Matsumoto S., Chikuma S., et al. Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer. J. Clin. Oncol. 2015; 33 (34): 4015-22. DOI: https://doi.org/10.1200/JCO.2015.62.3397
3. Hamanishi J., Mandai M., Iwasaki M., Okazaki T., Tanaka Y., Yamaguchi K., Higuchi T., Yagi H., Takakura K., Minato N., et al. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc. Natl. Acad. Sci. U S A. 2007; 104 (9): 3360-5. DOI: https://doi.org/10.1073/pnas.0611533104
4. Webb J.R., Milne K., Kroeger D.R., Nelson B.H. PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serous ovarian cancer. Gynecol Oncol. 2016; 141 (2): 293-302. DOI: https://doi.org/10.1016/j.ygyno.2016.03.008
5. Zhao B., Zhao H., Zhao J. Efficacy of PD-1/PD-L1 blockade monotherapy in clinical trials. Ther. Adv. Med. Oncol. 2020; 12: 1758835920937612. DOI: https://doi.org/10.1177/1758835920937612
6. Chen X.J., Yuan S.Q., Duan J.L., Chen Y.M., Chen S., Wang Y., Li Y.F. The Value of PD-L1 Expression in Predicting the Efficacy of Anti-PD-1 or Anti-PD-L1 Therapy in Patients with Cancer: A Systematic Review and Meta-Analysis. Dis Markers. 2020; 2020: 6717912. DOI: https://doi.org/10.1155/2020/6717912
7. Swiderska J., Kozlowski M., Nowak K., Rychlicka M., Branecka-Wozniak D., Kwiatkowski S., Pius-Sadowska E., Machalinski B., Cymbaluk-Ploska A. Clinical Relevance of Soluble Forms of Immune Checkpoint Molecules sPD-1, sPD-L1, and sCTLA-4 in the Diagnosis and Prognosis of Ovarian Cancer. Diagnostics (Basel). 2022; 12 (1): 189. DOI: https://doi.org/10.3390/diagnostics12010189
8. Niu M., Liu Y., Yi M., Jiao D., Wu K. Biological Characteristics and Clinical Significance of Soluble PD-1/PD-L1 and Exosomal PD-L1 in Cancer. Front Immunol. 2022; 13: 827921. DOI: https://doi.org/10.3389/fimmu.2022.827921
9. Oh S.Y., Kim S., Keam B., Kim T.M., Kim D.W., Heo D.S. Soluble PD-L1 is a predictive and prognostic biomarker in advanced cancer patients who receive immune checkpoint blockade treatment. Sci. Rep. 2021; 11 (1): 19712. DOI: https://doi.org/10.1038/s41598-021-99311-y
10. Chiarucci C., Cannito S., Daffina M.G., Amato G., Giacobini G., Cutaia O., Lofiego M.F., Fazio C., Giannarelli D., Danielli R., et al. Circulating Levels of PD-L1 in Mesothelioma Patients from the NIBIT-MESO-1 Study: Correlation with Survival. Cancers (Basel). 2020; 12 (2): 361. DOI: https://doi.org/10.3390/cancers12020361
11. Ding X.C., Wang L.L., Zhu Y.F., Li Y.D., Nie S.L., Yang J., Liang H., Weichselbaum R.R., Yu J.M., Hu M. The Change of Soluble Programmed Cell Death-Ligand 1 in Glioma Patients Receiving Radiotherapy and Its Impact on Clinical Outcomes. Front Immunol. 2020; 11: 580335. DOI: https://doi.org/10.3389/fimmu.2020.580335
12. Finkelmeier F., Canli O., Tal A., Pleli T., Trojan J., Schmidt M., Kronenberger B., Zeuzem S., Piiper A., Greten F.R., Waidmann O. High levels of the soluble programmed death-ligand (sPD-L1) identify hepatocellular carcinoma patients with a poor prognosis. Eur. J. Cancer. 2016; 59: 152-9. DOI: https://doi.org/10.1016/j.ejca.2016.03.002
13. Bailly C., Thuru X., Quesnel B. Soluble Programmed Death Ligand-1 (sPD-L1): A Pool of Circulating Proteins Implicated in Health and Diseases. Cancers (Basel). 2021; 13 (12): 3034. DOI: https://doi.org/10.3390/cancers13123034
14. Mortensen J.B., Monrad I., Enemark M.B., Ludvigsen M., Kamper P., Bjerre M., d’Amore F. Soluble programmed cell death protein 1 (sPD-1) and the soluble programmed cell death ligands 1 and 2 (sPD-L1 and sPD-L2) in lymphoid malignancies. Eur. J. Haematol. 2021; 107 (1): 81-91. DOI: https://doi.org/10.1111/ejh.13621
15. Fanale D., Brando C., Corsini L.R., Cutaia S., Di Donna M.C., Randazzo U., Filorizzo C., Lisanti C., Magrin L., Gurrera V., et al. Low plasma PD-L1 levels, early tumor onset and absence of peritoneal carcinomatosis improve prognosis of women with advanced high-grade serous ovarian cancer. BMC cancer. 2023; 23 (1): 437. DOI: https://doi.org/10.1186/s12885-023-10911-5
16. Buderath P., Schwich E., Jensen C., Horn P.A., Kimmig R., Kasimir-Bauer S., Rebmann V. Soluble Programmed Death Receptor Ligands sPD-L1 and sPD-L2 as Liquid Biopsy Markers for Prognosis and Platinum Response in Epithelial Ovarian Cancer. Front. Oncol. 2019; 9: 1015. DOI: https://doi.org/10.3389/fonc.2019.01015
17. Larrinaga G., Solano-Iturri J.D., Errarte P., Unda M., Loizaga-Iriarte A., Perez-Fernandez A., Echevarria E., Asumendi A., Manini C., Angulo J.C., Lopez J.I. Soluble PD-L1 Is an Independent Prognostic Factor in Clear Cell Renal Cell Carcinoma. Cancers (Basel). 2021; 13 (4): 667. DOI: https://doi.org/10.3390/cancers13040667
18. Gershtein E.S., Mochalova A.S., Korotkova E.A., Samoilova E.V., Vashketova O.I., Kuzmin Yu.B., Sokolov N.Yu., Kushlinskii N.E. Dynamics of soluble forms of immune checkpoint components PD-1/PD-L1/B7-H3, CD314/ULBP1 and HLA-G in the peripheral blood of melanoma patients treated with blockers of the programmed cell death protein PD-1. Bull. Expert. Biol. Med. 2023; 175 (4): 482-7. DOI: https://doi.org/10.1007/s10517-023-05891-2 (in Russian)
19. Barron C.C., Stefanova I., Cha Y., Elsolh K., Zereshkian A., Gaafour N., McWhirter E. Chronic immune-related adverse events in patients with cancer receiving immune checkpoint inhibitors: a systematic review. J. Immunother. Cancer. 2023; 11 (8): e006500. DOI: https://doi.org/10.1136/jitc-2022-006500
20. Quandt Z., Young A., Anderson M. Immune checkpoint inhibitor diabetes mellitus: a novel form of autoimmune diabetes. Clin. Exp. Immunol. 2020; 200 (2): 131-140. DOI: https://doi.org/10.1111/cei.13424
21. Borunova A.A., Shoua E.K., Zakharova E.N., Chertkova A.I., Kadagidze Z.G., Shoua I.B., Davydova T.V., Kushlinskii N.E., Babkina I .V., Osipova N.G., Ternavsky A.P., Doroshev I.A., Kononets P.V., Stilidi I.S., Zabotina T.N. Features of cellular immunity of medical workers in the first wave of the SARS-COV2 infection pandemic. Immunology. 2023; 44 (6): 776-87. DOI: https://doi.org/10.33029/0206-4952-2023-44-6-776-787 (in Russian)
22. Pacholczak-Madej R., Kosałka-Węgiel J., Kuszmiersz P., Mituś J.W., Püsküllüoğlu M., Grela-Wojewoda A., Korkosz M., BazanSocha S. Immune Checkpoint Inhibitor Related Rheumatological Complications: Cooperation between Rheumatologists and Oncologists. Int. J. Environ Res. Public Health. 2023; 20 (6): 4926. DOI: https://doi.org/10.3390/ijerph20064926
23. Pichugin A.V., Podsvirova S.A., Ushakova E.I., Spirin D.M., Lebedeva E.S., Ataullakhanov R.I. Reprogramming of myeloid cells of the tumor microenvironment increases the effi ciency of CTLA-4 and PD-1 blockade in experimental malignant melanoma immunotherapy. Immunologiya. 2022; 43 (6): 673–90. DOI: https://doi.org/10.33029/0206-4952-2022-43-6-673-690 (in Russian)